IMMP2L has been suggested as a candidate susceptibility gene in GTS (3, 6), and we have shown that intragenic IMMP2L deletions were present at a higher frequency in GTS patients compared to control population. This evidence concerns the gene IMMP2L and Tourette syndrome.